DHT.UN vs. ATT, AGRA, MJ, BIO, BBM, BAMM, LOVE, CSI, CALI, and DCNN
Should you be buying DRI Healthcare Trust stock or one of its competitors? The main competitors of DRI Healthcare Trust include Abattis Bioceuticals (ATT), Agraflora Organics International (AGRA), Amplify Alternative Harvest ETF (MJ), Bio-Rad Laboratories (BIO), Blueberries Medical (BBM), BooksAMillion (BAMM), Cannara Biotech (LOVE), Chemesis International (CSI), China Auto Logistics (CALI), and Digicann Ventures (DCNN). These companies are all part of the "drug manufacturers - specialty & generic" industry.
DRI Healthcare Trust vs.
DRI Healthcare Trust (TSE:DHT.UN) and Abattis Bioceuticals (CNSX:ATT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, community ranking, dividends, analyst recommendations and institutional ownership.
Abattis Bioceuticals received 69 more outperform votes than DRI Healthcare Trust when rated by MarketBeat users. However, 76.19% of users gave DRI Healthcare Trust an outperform vote while only 64.89% of users gave Abattis Bioceuticals an outperform vote.
48.4% of DRI Healthcare Trust shares are held by institutional investors. 0.1% of DRI Healthcare Trust shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
DRI Healthcare Trust has a net margin of 5.02% compared to Abattis Bioceuticals' net margin of 0.00%. DRI Healthcare Trust's return on equity of 2.06% beat Abattis Bioceuticals' return on equity.
DRI Healthcare Trust currently has a consensus target price of C$17.94, indicating a potential upside of 45.60%. Given DRI Healthcare Trust's stronger consensus rating and higher probable upside, equities research analysts clearly believe DRI Healthcare Trust is more favorable than Abattis Bioceuticals.
In the previous week, DRI Healthcare Trust had 1 more articles in the media than Abattis Bioceuticals. MarketBeat recorded 1 mentions for DRI Healthcare Trust and 0 mentions for Abattis Bioceuticals. DRI Healthcare Trust's average media sentiment score of 1.08 beat Abattis Bioceuticals' score of 0.00 indicating that DRI Healthcare Trust is being referred to more favorably in the media.
DRI Healthcare Trust has higher revenue and earnings than Abattis Bioceuticals.
Summary
DRI Healthcare Trust beats Abattis Bioceuticals on 12 of the 13 factors compared between the two stocks.
Get DRI Healthcare Trust News Delivered to You Automatically
Sign up to receive the latest news and ratings for DHT.UN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DHT.UN vs. The Competition
DRI Healthcare Trust Competitors List
Related Companies and Tools
This page (TSE:DHT.UN) was last updated on 1/21/2025 by MarketBeat.com Staff
Free DHT.UN Stock Alerts